Novacyt S.A. Liquidity Agreement Update and Total Voting Rights (2596T)
02 July 2018 - 8:45PM
UK Regulatory
TIDMNCYT
RNS Number : 2596T
Novacyt S.A.
02 July 2018
Liquidity Agreement Monthly Update and
Total Voting Rights
Paris, France and Camberley, UK - 2 July 2018 - Novacyt
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, today announces its monthly update in
relation to ordinary shares traded under its ongoing liquidity
agreement with Invest Securities SA (the "Liquidity Agreement").
The Liquidity Agreement is governed by French law and is further
summarised in the 'notes for editors' section below.
During the period from 1 June to 30 June 2018, Invest Securities
purchased 10,008 ordinary shares at a maximum price of EUR0.72 and
a minimum price of EUR0.66 and sold 7,508 ordinary shares at a
maximum price of EUR0.72 and a minimum price of EUR0.68 under the
Liquidity Agreement. The total number of ordinary shares in the
Company, which are held in treasury as at close of business on 30
June 2018, is 86,871.
Total Voting Rights
The total number of ordinary shares in the Company remains
37,664,341. This figure may be used by shareholders as the
denominator for calculations by which they will determine if they
are required to notify their interest in, or a change to their
interest in, the Company pursuant to Article L. 223-7 of the French
Commercial Code and the Company's Articles. The Company is not
subject to the disclosure guidance and transparency rules made by
the Financial Conduct Authority under Part VI of FSMA.
For further information, please refer to www.novacyt.com or
contact:
Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1223 395472
Stifel Nicolaus Europe Limited (Nominated Advisor and Joint
Broker)
Jonathan Senior / Fred Walsh / Ben Maddison
+44 (0)20 7610 7600
WG Partners (Joint Broker)
Nigel Birks / Chris Lee / Claes Spång
+44 (0) 203 705 9330
FTI Consulting (International)
Brett Pollard / Victoria Foster Mitchell
+44 (0)20 3727 1000
brett.pollard@fticonsulting.com /
victoria.fostermitchell@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines / Astrid Villette
+33 (0)147 03 69 47 / +33 (0)147 03 69 51
arnaud.decheffontaines@fticonsulting.com /
astrid.villette@fticonsulting.com
About Novacyt Group
The Novacyt Group is a rapidly growing, international
diagnostics group with a growing portfolio of cancer and infectious
disease products and services. Through its proprietary technology
platform, NOVAPrep(R), and molecular platform, genesig(R), Novacyt
is able to provide an extensive range of oncology and infectious
disease diagnostic products across an extensive international
distributor network. The Group has diversified sales from
diagnostic reagents used in oncology, microbiology, haematology and
serology markets, and its global customers and partners include
major corporates.
Further information on the Liquidity Agreement
On 12 September 2016, the Company and Invest Securities entered
into the Liquidity Agreement pursuant to which Invest Securities
provides liquidity services in relation to the ordinary shares to
the Company. Invest Securities may purchase ordinary shares on
behalf of the Company under the agreement, subject to approval from
Shareholders as to price at which ordinary shares can be brought
back and the aggregate amount that the Company may provide to
Invest Securities to purchase such ordinary shares.
Shareholder approval was granted at the Shareholders' meeting
held on 27 June 2017 for the purchase of ordinary shares by Invest
Securities under the agreement at a maximum purchase price per
ordinary shares of EUR8.10 for an aggregate maximum purchase price
of EUR100,000 and for 18 months from the date of the approval.
Under the agreement, Invest Securities must act completely
independently of the Company and the Company must not communicate
with the employees of Invest Securities who are responsible for
performing the agreement. Invest Securities is paid EUR10,000 per
annum for its services under the liquidity agreement. The agreement
has an initial term of two years, with a rolling extension of one
year thereafter. The agreement can be terminated by either party at
the end of each such period subject to two months' prior notice.
The Liquidity Agreement is governed by French law. Ordinary shares
purchased by Invest Securities are either cancelled or held as
treasury shares (which are non-voting and do not rank for
dividends).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVRFKBDQKBKDBOK
(END) Dow Jones Newswires
July 02, 2018 06:45 ET (10:45 GMT)
Novacyt (LSE:NCYT)
Historical Stock Chart
From Apr 2024 to May 2024
Novacyt (LSE:NCYT)
Historical Stock Chart
From May 2023 to May 2024